In this Webinar you will learn about Almac\u2019s:<\/strong><\/p>\n\n\n\n \u2022 Novel strategy for patient stratification in basket & umbrella trials A changing clinical trial landscape<\/strong><\/p>\n\n\n\n The clinical trial landscape for precision medicine has shifted significantly in recent years towards multiple biomarkers being used to select patients for multiple therapies (umbrella studies) or include patients from multiple cancer types (basket studies). Diagnostic solutions for multi-arm clinical trial design<\/strong><\/p>\n\n\n\n Almac Diagnostic Services has created novel panel solutions for complex clinical trials \u2013 enabling clients to evaluate multiple biomarkers from one sample, whilst saving precious tissue, time and cost. Almac offer a full portfolio of DNA and RNA assays which can be run using dual extraction from one FFPE sample. When combined, the assays provide a comprehensive review of tumour biology, the results of which are presented in an easily interpreted patient molecular data report which can be tailored to client requirements.<\/p>\n","protected":false},"featured_media":0,"template":"","diagnostics_type":[474],"class_list":["post-1156","diagnostic_resource","type-diagnostic_resource","status-publish","hentry","diagnostics_type-diagnostics-webinars"],"acf":[],"yoast_head":"\n
\n \u2022 A solution to enable multiple biomarkers to be evaluated from one sample
\n \u2022 DNA & RNA panel solutions for translational research & clinical trial use
\n \u2022 Customised patient reporting enabling simple interpretation of molecular data<\/p>\n\n\n\n
\n When multiple biomarkers are required in these types of studies, this usually involves complex logistics with multiple vendors and excessive sample requirements which can increase time to manage and cost to run.<\/p>\n\n\n\n